{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-199882","form_type":"8-K","ticker":"SLNO","cik":"0001484565","company_name":"SOLENO THERAPEUTICS INC","filed_at":"2025-09-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.088301+00:00","generated_at":"2026-05-17T06:58:58.579194+00:00","sec_items":["7.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Soleno reports death of VYKAT XR patient; company says not drug-related","bullets":["A 17-year-old male with lymphedema, thrombophlebitis, and obesity died from pulmonary embolus; FAERS report filed.","Treating physician and Soleno assessed the death as not related to VYKAT XR treatment.","Soleno reaffirms VYKAT XR safety profile and urges use per FDA-approved label.","Company will not comment on future adverse events unless directly linked to VYKAT XR and unexpected per label.","Prader Willi Syndrome patients have reduced life expectancy; mean age of death is 29.5 years per 40-year study."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-199882","json":"https://secwatch.observer/filing/0001193125-25-199882.json","markdown":"https://secwatch.observer/filing/0001193125-25-199882.md","text":"https://secwatch.observer/filing/0001193125-25-199882.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484565/000119312525199882/0001193125-25-199882-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484565/000119312525199882/d88981d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:58:58.579194+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}